Home      About     Team      Clients      Publications      Contact            

  Bioscience Valuation's unique approach to portfolio management clearly enhanced the value of our R&D pipeline.

Prof. Dr. Klaus Nickisch, CSO Evestra Inc., formerly Head of Project Management at Bayer Schering Pharma AG

Core Services
  Commercial Assessment &

  R&D Risk Analysis &
Productivity Increase

  Financial Valuation
  Portfolio Management
  Investment Decisions
  Partnering / Licensing
  Corporate Finance / M&A

Special Expertise
  Economic Modeling
of Healthcare Systems

  Assessing the Economics
of Personalized Medicine

  Corporate Partnership Program

  Market Model
  R&D Risk Model
  Valuation Model

Bioscience Valuation, a Leader in Evidence-Based Evaluations
Bioscience Valuation provides evidence-based value, commercial, R&D, and economic assessments to pharmaceutical and biotechnology companies. These assessments support investment and partnering decisions.

Each analysis covers the entire spectrum of commercial, R&D and financial variables. Our appraisals are based on Bioscience Valuation's profound subject expertise and long-standing experience, and are backed by comprehensive research taking advantage of Bioscience Valuation's extensive databases.

Pharmaceutical companies use our services to
  • Determine project value and support portfolio management decisions
  • Assess in-licensing candidates and potential M&A transactions
  • Forecast a drug's sales potential (primary and secondary market research, pharmacoeconomics)
  • Increase R&D productivity
  • Optimize resource planning and capacity utilization
Biotech companies use our services to
  • Identify licensing partners, optimize term sheets and negotiate value-maximizing agreements
  • Prepare funding rounds and attract investors
Healthcare companies and organizations use our services to
  • Assess the economic impact of healthcare policies
  • Facilitate healthcare policy decisions
Investors use our services to
  • Facilitate investment decisions
  • Support their due diligence efforts